Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04354025
Other study ID # 20-x130
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 30, 2023
Est. completion date July 31, 2028

Study information

Verified date March 2023
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML. Previous studies in adults with AML sowed successful induction of remission and a previous phase 1 study demonstrated that CIML NK cells can be used safely in pediatric patients. This phase 2 study uses FLAG chemotherapy to lower leukemic burden and suppress the recipient's immune system to provide an optimal environment for CIML NK cell expansion and anti-leukemic activity.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 31, 2028
Est. primary completion date September 30, 2026
Accepts healthy volunteers No
Gender All
Age group 1 Year to 21 Years
Eligibility Inclusion Criteria: - Refractory AML without complete remission (CR) after induction therapy (primary induction failure) or relapsed AML after obtaining a CR. Disease defined by one of the following: *= 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary disease *absolute blast count greater than 1,000 per microliter in the peripheral blood with or without extramedullary disease. - Age requirement for pediatric cohort: 1-21 years of age. - Available HLA-haploidentical donor that meets the following criteria: - Related donor (parent, sibling, offspring, or offspring of sibling) - At least 18 years of age - HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus. - In general, good health and medically able to tolerate leukapheresis required for harvesting the NK cells for this study. - Negative for hepatitis, HTLV, and HIV on donor viral screen - Not pregnant - Voluntary written consent to participate in this study - Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment. - Karnofsky/Lansky performance status > 50 % - Adequate organ function as defined below: - Total bilirubin < 2 mg/dL - AST(SGOT)/ALT(SGPT) < 3.0 x upper limit of normal (ULN) - Creatinine within normal institutional limits OR creatinine clearance > 50 mL/min/1.73 m2 by Schwartz formula or GFR (See Appendix B) - Oxygen saturation =90% on room air - Ejection fraction =35% - Able to be off corticosteroids and any other immune suppressive medications beginning on Day -3 and continuing until 30 days after the infusion of the CIML NK cells. However, use of low-level corticosteroids is permitted if deemed medically necessary. Low-level corticosteroid use is defined as 10mg or less of prednisone (or equivalent for other steroids) per day. - Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the DLT evaluation period. - Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Exclusion Criteria: - Relapsed after allogeneic transplantation. - Isolated extramedullary relapse - Circulating blast count >30,000/µL by morphology or flow cytometry (cytoreductive therapies including leukapheresis or hydroxyurea are allowed). - Patients with any of the following diagnoses: - Down's syndrome - Acute promyelocytic leukemia (APL) - Juvenile myelomonocytic leukemia (JMML) - Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection. - Known hypersensitivity to one or more of the study agents. - Received any investigational drugs within the 14 days prior to the first dose of fludarabine. - Pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Cytokine induced memory-like NK cells
-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
Drug:
Fludarabine
-Fludarabine (dose: 30 mg/m^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
Ara-C
-Ara-C (dose: 2000mg/m^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
G-CSF
-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
Interleukin-2
-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
Procedure:
Leukapheresis
-Donor only

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate (complete remission (CR) plus complete remission with incomplete blood count recovery (CRi)) Complete remission (CR) requires all of the following:
Bone marrow:
Morphologically leukemia free state (= 5% myeloblasts) with normal maturation of all cell lines. Persistent dysplasia may be noted
Peripheral blood:
Platelets = 100,000/uL
Neutrophils = 1000/uL
Complete remission with incomplete blood count recovery (CRi):
All of the above criteria for CR must be met, except that absolute neutrophils <1000/µL or platelets <100,000 /µL in the blood.
Day 28
Primary Percentage of patients able to proceed to stem cell transplant Up to 60 days
Secondary Disease-free survival (DFS) -DFS is defined as the time from the day CR or CRi is documented until disease progression or death. Up to 2 years
Secondary Overall survival (OS) -OS is defined from the date of first dose of fludarabine on this study until death. Up to 2 years
Secondary Percentage of patients who achieve minimum residual disease (MRD)-negative status Day 28
Secondary Safety of regimen as measured by number of adverse events -Adverse events will be collected from Day 0 to Day 35; however, bone marrow suppression (ANC = 500/mcL) and adverse events of GVHD involving the liver, skin, or gastrointestinal tract will be recorded to Day 100 From Day 0 to Day 100
Secondary Duration of remission Up to 2 years
Secondary Time to progression Up to 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02890329 - Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04975919 - Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Terminated NCT02882321 - Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03214562 - Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Phase 2
Completed NCT02509546 - 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT03683433 - Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Phase 2
Completed NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia N/A
Completed NCT02070458 - Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03557970 - JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Recruiting NCT03661307 - Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03629171 - Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Phase 2
Recruiting NCT05396859 - Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Phase 1
Terminated NCT03067571 - Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase 2
Completed NCT04146038 - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Phase 2
Suspended NCT03128034 - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Phase 1/Phase 2
Active, not recruiting NCT04207190 - Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04047641 - Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase 1/Phase 2
Withdrawn NCT04493099 - Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML Phase 1/Phase 2